1. Huntsman Cancer Institute University of Utah, Salt Lake City, UT;
2. ARIAD Pharmaceuticals, Inc., Cambridge, MA;
3. University of California San Francisco, San Francisco, CA;
4. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
5. Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea;
6. Centre Hospitalier Lyon Sud, Pierre Benite, & INSERM U1052, Lyon, France;
7. Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI;
8. Department of Hematology-Oncology “L. and A. Seragnoli,” S. Orsola-Malpighi University Hospital, Bologna, Italy;
9. III. Med. Klinik, Universitätsmedizin Mannheim, Mannheim, Germany;
10. MolecularMD, Portland, OR;
11. Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and
12. INSERM Clinical Investigation Center 1402, Centre Hospitalier et Universitaire de Poitiers, France;
13. Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy;
14. Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany;
15. SA Pathology and South Australian Health and Medical Research Institute, Adelaide, Australia;
16. School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia